Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571701 · ClinicalTrials.gov registry record · Phase 2
Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis
A Phase 2 study, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00571701 is a Phase 2 study that has completed, run by Northwell Health. The registered enrollment target is 50 participants.
The verdict
NCT00571701, a Phase 2 study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a randomized double blind controlled study to determine if celebrex (celecoxib), a selective COX-2 inhibitor, can decrease the rate of recurrence in adult and pediatric patients with recurrent respiratory papillomatosis. All patients will be evaluated for disease severity at enrollment and at 3 month intervals for 30 months. After randomization, patients in the early treatment arm will begin celecoxib 6 months after enrollment. The delayed treatment arm will begin celecoxib 18 months after enrollment. All patients will receive celecoxib for 1 year. During the time that patients do not receive celecoxib, they will receive a placebo capsule with the same appearance. Follow-up visits will occur at three month intervals for the duration of the study.
Interventions
- DRUG placebo
- DRUG celebrex (celecoxib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2008-02 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00571701
The ClinicalTrials.gov registry entry for NCT00571701 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00571701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00571701 about?
NCT00571701 is a clinical study titled "Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis". This is a randomized double blind controlled study to determine if celebrex (celecoxib), a selective COX-2 inhibitor, can decrease the rate of recurrence in adult and pediatric patients with recurrent respiratory papillomatosis. All patients will be evaluated for disease severity at enrollment and a...
What is the current status of trial NCT00571701?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2008-02. Estimated completion is 2015-01.
What interventions are being tested in trial NCT00571701?
The interventions under investigation include: placebo (DRUG), celebrex (celecoxib) (DRUG).
Who is sponsoring clinical trial NCT00571701?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.